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Abstract
Introduction: XMRV is a gammaretrovirus that was thought to be associated with prostate cancer (PC) and chronic fatigue
syndrome (CFS) in humans until recently. The virus is culturable in various cells of human origin like the lymphocytes, NK
cells, neuronal cells, and prostate cell lines. MicroRNAs (miRNA), which regulate gene expression, were so far not identified
in cells infected with XMRV in culture.
Methods: Two prostate cell lines (LNCaP and DU145) and two primary cells, Peripheral Blood Lymphocytes [PBL] and
Monocyte-derived Macrophages [MDM] were infected with XMRV. Total mRNA was extracted from mock- and virus-infected
cells at 6, 24 and 48 hours post infection and evaluated for microRNA profile in a microarray.
Results: MicroRNA expression profiles of XMRV-infected continuous prostate cancer cell lines differ from that of virus-
infected primary cells (PBL and MDMs). miR-193a-3p and miRPlus-E1245 observed to be specific to XMRV infection in all 4
cell types. While miR-193a-3p levels were down regulated miRPlus-E1245 on the other hand exhibited varied expression
profile between the 4 cell types.
Discussion: The present study clearly demonstrates that cellular microRNAs are expressed during XMRV infection of human
cells and this is the first report demonstrating the regulation of miR193a-3p and miRPlus-E1245 during XMRV infection in
four different human cell types.
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Introduction
XMRV is a recently identified gammaretrovirus, closely related
to xenotropic murine leukemia viruses (MLVs), that was initially
detected in familial cases of prostate cancer tissue using a virus gene
array [1]. XMRV was also detected in blood cells of patients with
Chronic Fatigue Syndrome (CFS) and normal healthy controls
[2,3]. Subsequently, a number of additional studies have failed to
confirm any association of XMRV with CFS or prostate cancer [4–
11]. Indeed, recent reports suggest that XMRV likely originated as
a laboratory contaminant in prostate xenografts serially passaged
through nude mice by the recombination of endogenous MLVs.
Though the XMRV is of murine origin, it is known to infect
different human cell types like T and B lymphocytes, NK cells,
prostate cancer cell lines, and neuronal cells [12–15]. Various
detection methods like serology, cell culture, and nucleic-acid based
assays have already been used for detecting XMRV infection
[4,12,16–19]. However, use of microRNAs (miRNAs) as biomark-
ers of XMRV infection has not been reported so far.
MicroRNAs have known to play a critical role in the life cycle of
retroviruses and a few oncogenic viruses such as reticuloendothe-
liosis virus strain T (REV-T), Epstein-Barr virus and Hepatitis C
virus (HCV) wherein the viruses regulate host cells and viral
replication through specific microRNAs [20–23]. MicroRNAs are
a class of evolutionarily conserved, endogenous, small non-coding
RNAs that regulate gene expression and play a role in diverse
cellular processes, including proliferation, differentiation and cell
death [24]. As an abundant class of regulatory molecules, there are
hundreds of distinct miRNAs identified in the human genome to
date and hundreds more predicted. A single miRNA can regulate
expression of multiple genes, and expression of a single gene may
be regulated by several distinct miRNAs, creating complicated
regulatory networks. It is estimated that roughly 60% of human
protein-coding genes are regulated by miRNAs [25–28].
In this study, we evaluated whether miRNAs are modulated by
XMRV in cultured cells and if so, can they be identified to see
whether a single or a set of miRNAs specific to the infection can be
detected early that could serve as biomarker(s) of XMRV
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e32853infection. Our results demonstrate that a) two miRNAs, miR-
193a-3p and miRPlus-E1245 (a proprietary sequence of Exiqon
Inc, Denmark and named as such to differentiate from miR-1245)
were commonly regulated among all 4 cell types infected with
XMRV used in the study, and b) while miR-193a-3p is down
regulated, miRPlus-E1245 exhibited varied expression profile in
the four cell types infected with XMRV.
Materials and Methods
Cell culture and isolation and culture of Peripheral Blood
Lymphocytes (PBL)
LNCaP (ATCC, Manassas, VA) and DU145 cells (kind gift
from Robert Silverman, Cleveland Clinic, Ohio to Indira Hewlett)
were cultured in RPMI 1640 supplemented with 10% FBS, 2 mM
glutamine, 100 units/ml of penicillin, and 100 units/ml strepto-
mycin [29,30]. PBMC were isolated from the peripheral blood of
HIV seronegative donors (NIH Blood Bank) by Ficoll/Hypaque
density gradient centrifugation. Monocytes were removed by
adherence to the culture flasks and the remaining Peripheral Blood
Lymphocytes (PBL) were stimulated with 2 mg/ml PHA for 3 days
to activate T cells before infection. The PBL were cultured in
RPMI 1640 supplemented with 10% FBS, 2 mM glutamine,
100 units/ml of penicillin, 100 units/ml of streptomycin, and
5 units/ml of human Interleukin-2 (Roche, NJ) until further use.
Isolation and culture of Monocyte-derived Macrophages
(MDMs)
Monocytes were isolated from PBMC of donors seronegative for
HIV-1 and hepatitis B after leukopheresis and purified by
countercurrent centrifugal elutriation [31]. Cell suspensions
contained .95% monocytes by criteria of cell morphology on
Wright-stained cytosmears, by granular peroxidase and by non-
specific esterase. The cells were cultured for 5 days in DMEM
supplemented with 10% FBS, 2 mM glutamine, 100 units/ml of
penicillin, and 100 units/ml streptomycin and 1000 U/ml mac-
rophage colony stimulation factor (M-CSF) before infection with
XMRV. All cell culture reagents were tested by Limulus Lysate
assay (Associates of Cape Cod, Cape Cod, MA) for endotoxin
contamination and the levels were found to be ,0.06 EU/ml.
Infection with XMRV
Prostate cell lines LNCaP and DU145, Peripheral Blood
Lymphocytes (PBL) and Primary monocyte-derived macrophages
(MDM) were infected with 1610
7 XMRV copies/mL. After a
three-hour exposure, virus particles were removed, and fresh
medium was added and cultured at 37uC. Infected cells were
isolated at the indicated times, washed twice in 16PBS and stored
at –80uC until further use.
Cellular total mRNA extraction
Total RNA from the four cell types stored as above was extracted
by using miRCURY
TM RNA isolation kit as per the manufacturer’s
instructions (Exiqon, Denmark). The final volume of RNA
extracted from each column was approximately 75–100 ml which
was quantified by NanovueH Plus spectrophotometer (GE Life
Sciences, Piscataway, NJ). All the above experiments were
conducted twice and RNAs extracted from duplicate experiments
were analyzed for microRNA (miR) expression profile.
Quantitative RT-PCR
The endogenous human Glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) control real-time PCR primers and probes
(TaqMan endogenous human GAPDH control, Cat# 4352934E)
and the XMRV gag gene specific real-time PCR primers and
probes were obtained from Applied Biosystems, Foster City, CA.
Thermal cycling was performed for XMRV and GAPDH in
triplicate on RNA samples in a Micro-Amp Optical 96-well
reaction plate (Applied Biosystems, Foster City, CA). Briefly, an
equal amount of total RNA was used to quantify XMRV levels
using QuantiTect Probe RT-PCR kit (Qiagen Inc., Valencia, CA).
Real-time PCR Master Mix (Quantitect Probe RT-PCR, Qiagen
Inc., Valencia, CA) was added to the RNA, forward (CGA-
GAGGCAGCCATGAAGG) and reverse (CCCAGTTCCCG-
TAGTCTTTTGAG) gag primers, probe (6FAM-AGTTCTA-
GAAACCTCTACACTC-MGBNFQ) and primer for XMRV
viral RNA first strand synthesis (reverse-transcription) (GA-
GATCTGTTTCGGTGTAATGGAAA) in a total volume of
25 mL. The mixture was incubated at 50uC for 2 min (for RNA,
20 min), at 95uC for 10 min, and then cycled at 95uC for 15 sec
and 60uC for 60 sec 40 times, in an Applied Biosystems 7500
sequence detection system. XMRV levels were quantified using
XMRV clone VP62-pcDNA3.1 (GenBank accession no.
EF185282; obtained through NIH AIDS Research and Reference
Reagent Program) as a standard. Each experimental sample was
normalized relative to the GAPDH endogenous control and the
relative amount of target gene quantified.
Assessment of miRNA Quality and Array analysis
MicroRNA array services were contracted out to Exiqon
Services, Denmark. The quality of the total RNA was verified
by an Agilent 2100 Bioanalyzer profile. 1000 ng total RNA from
sample and reference was labeled with Hy3
TM and Hy5
TM
fluorescent label, respectively, using the miRCURY LNA
TM
microRNA Power Labeling Kit, Hy3
TM/Hy5
TM (Exiqon, Den-
mark) following the procedure described by the manufacturer. The
Hy3
TM-labeled samples and a Hy5
TM-labeled reference RNA
sample were mixed pair-wise and hybridized to the miRCURY
LNA
TM microRNA Array (5th gen-hsa, mmu & rno) (Exiqon,
Denmark), which contains capture probes targeting all miRNAs
for human, mouse or rat registered in the miRBASE 16.0. The
hybridization was performed according to the miRCURY LNA
TM
microRNA Array instruction manual using a Tecan HS 4800
TM
hybridization station (Tecan, Austria). After hybridization the
microarray slides were scanned and stored in an ozone free
environment (ozone level below 2.0 ppb) in order to prevent
potential bleaching of the fluorescent dyes. The miRCURY
TM
LNA array microarray slides were scanned using the Agilent
G2565BA Microarray Scanner System (Agilent Technologies,
Inc., USA) and the image analysis was carried out using the
ImaGene 9.0 software (BioDiscovery, Inc., USA). The quantified
signals were background corrected (normal exposure with offset
value 10) and normalized using the global LOWESS (LOcally
WEighted Scatterplot Smoothing) regression algorithm [32].
Results
Quantitative RT-PCR demonstrates XMRV infection in all
4 cell types studied
XMRV infection in the 4 cell types was determined by
performing a quantitative RT-PCR (qPCR) on the total RNAs
extracted at various time points. Endogenous GAPDH levels were
used for normalizing the expression levels of the XMRV gag target
gene. Results demonstrated that XMRV was able to infect all 4
cells types studied, very robustly in the prostate cell lines (LNCaP
and DU145) and moderately in PBLs and MDMs (Fig. 1). A 3–10
Cellular microRNA Profiles of XMRV Infection
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all 4 cell types (Fig. 1).
MicroRNA expression profiles of XMRV infected
continuous cell lines differ from that of infected primary
cells (PBL and MDMs)
PrincipalComponentAnalysis(PCA),amethodusedforreducing
the dimension of large data sets and thereby useful to explore
naturally arising sample classes/groups based on expression profile
was performed. By including the microRNAs that have the largest
variation acrossall samples (SD.1)an overview ofhow the samples
cluster based on this variance is obtained. Based on this method, if
the biological differences between various samples are pronounced,
then this would become a primary component of the variation
leading to segregation of samples in different regions of a PCA plot
corresponding to their biology. As demonstrated in Fig. 2, it is
observed that the overall miRNA expression profile in LNCaP and
DU145 cell lines form a tight cluster suggesting minimal variation
duetotimeandinfectionstatusofthesetwocelltypes,whilethePBLs
andMDMprofilesaremorespread,indicatingtheglobalmiRlevels
being affected both due to time and infection status.
Heat map analysis and unsupervised hierarchical
clustering
MicroRNA expression profiles from four different XMRV-
infected cell types at 3 different time points were plotted on a heat
map. As observed in Fig. 3, the heat map diagram depicts results
of the two-way hierarchical clustering of microRNAs and samples.
Each row representing one miRNA and each column representing
one sample confirms the variation in miRNA expression profile
between the continuous prostate cancer cell lines (LNCaP and
DU145) and the PBLs and MDMs. A more distinct pattern of
demarcation in miRNA profiles between these two set of cell types
is observed in the region of the heat map depicting miR-1275 to
miR-765 (Fig. 3). The microRNA clustering tree is shown on left of
the figure.
miR-193a-3p and miRPlus-E1245 are specific to XMRV
infection in all 4 cell types
The main objective of the current study was to identify common
miRNAs that are uniformly regulated in all 4 cells types due to
XMRV infection and hence an overall comparative analysis was
performed. While comparing the two sample groups (mock versus
infected) using a paired t-test, no microRNA was found to be
differentially expressed using a cut-off of p-value,0.05. Since the
experiment involved 4 cell lines that behave differently, with two
treatments (mock- and virus-treated) and 3 time-points (6 h, 24 h
and 48 h), a more logical approach was adopted to simply look
into the differences between the two treatments over the three
time-points, by subtracting the control (mock) from the virus
treatment. Subsequently, the most differentially expressed genes
between the 3 time points (6 h to 24 h and 48 h) was estimated. As
represented in a venn diagram (Fig. 4) a total of 72 differentially
Figure 1. Quantitative-PCR analysis of XMRV infection. Total mRNA from (A) LNCaP, (B) DU145, (C) PBLs and (D) MDM cells either mock- or
virus-treated were subjected to RT-PCR using the gag primers for detecting XMRV infection. GAPDH primers were used as endogenous controls. As
evident, XMRV was able to infect all 4 cell types with substantial increase in infection by the 48 h time point.
doi:10.1371/journal.pone.0032853.g001
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Among these, 2 miRs were common in all 4 cell types, while
6 miRs were found to be common in 3 of the 4 cell types and 11
miRs were common in at least 2 of the 4 cell types.
Further analysis of the top 25 differentially expressed miRs
between the 4 cell types revealed that the two miRNAs common to
all 4 cell types were miR-193a-3p and miRPlus-E1245 (Fig. 5).
The miRPlus-E1245 is a recently discovered miRNA and
proprietary sequence of Exiqon Inc, Denmark and named as
such to differentiate it from miR-1245. The sequence is not yet
annotated and hence not been submitted to the miRNA database
yet. More significantly, though the miRPlus-E1245 levels were in
the top 25 list in one experiment and moderately regulated in the
second experiment, the miR-193a-3p expression profile was
among the top 25 list in both the microarray experiments. The
reason for the observed differences in the relative abundance of the
differentially expressed miRNAs could be due to donor-to-donor
variations. MicroRNAs that were common in 3 of the 4 cell types
were miR-15a, miR-19a, miR-29b, miR-32, miR-33a, and miR-
101. Eleven microRNAs that were differentially expressed and
common in 2 of the 4 cell types were found to be miR-17, miR-21,
miR-29c, miR-141, miR-142-3p, miR-215, miR-494, miRPlus-
E1072, miRPlus-E1192, miR-1248, and miR-1973 (Fig. 5).
miR-193a-3p is down regulated and miRPlus-E1245
exhibits varied expression profile
Following the identification of 2 miRs (miR-193a-3p and
miRPlus-E1245) that were specific to all 4 cell types infected with
XMRV, it was logical to deduce the expression profile of these two
miRNAs in all 4 cell types over time in virus-infected cells. By
subtracting the miRNA expression values from the virus-infected
and mock-infected (M-V) and further subtracting the values thus
generated between the time points (nT6-nT24 and nT6-nT48),
an expression profile was generated for the two miRNAs as
mentioned above. It can be observed in figure 5 that miR-193a-3p
is down regulated over time due to the virus infection in all 4 cell
types. The miRPlus-E1245 however exhibits varied levels of
expression profile between the 4 cell types with up regulation in
MDM and PBL cell types and down regulation in LNCaP and
DU145 cell types (Fig. 6).
Discussion
The discovery of XMRV and its potential association with PC
and CFS aroused considerable excitement and promise within the
research and clinical community regarding a possible infectious
etiology for at least some cases of these disease or conditions.
[2,3,33]. However,recent research findings havenot supported any
association between the virus and CFS or prostate cancer
[7,9,10,34–37]. In fact, the virus itself may have originated as a
result of recombination in a laboratory setting [38,39]. Specifically,
it has been postulated that XMRV originated as a result of
recombination between two MLV proviruses in laboratory mice
[40]. These findings appear to raise doubts about the significance
and involvement of XMRV in any human disease or condition
[38–41]. Nonetheless, because at least some studies have
demonstrated that XMRV is a culturable virus and that it can
readily infect cells of human origin [12–15], additional research
efforts will help to further our understanding of XMRV
pathogenesis and provide insights into the modes of transmission
involved in XMRV infection. It also remains to be seen whether
Figure 2. Principal Component Analysis (PCA) Plot. The principal component analysis is performed on all samples and on all microRNAs with
standard deviation over 1. The normalized log ratio values have been used for the analysis. Abbreviations: LM (LNCaP Mock); LV (LNCaP Virus-treated);
DM (DU145 Mock); DV (DU145 Virus-treated); PM (PBL Mock); PV (PBL Virus-treated); and MM (MDM Mock); MV (MDM Virus-treated). The LNCaP and
DU145 cell lines form tight cluster indicating minimal variation with regard to infection status and time. PBLs and MDMs are more spread suggesting
variation due to both and time and infection status.
doi:10.1371/journal.pone.0032853.g002
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[12,37,41].
The present study further emphasizes that XMRV can infect
human prostate and hematopoietic cells and the study clearly
demonstrates that microRNAs are regulated during XMRV
infection of these culturable human cells. In fact, the qPCR results
indicate that while all the 4 cell types were susceptible to XMRV
infection with significant increase in viral titers by 48 h time point it
was evident that there was a distinct difference in infection levels
between the 4 cell types (Fig. 1). The prostate cell lines (LNCaP and
DU145) supported robust XMRV infection, while the PBLs and
MDMs were moderately infected. It is interesting to note that the
variability in infection status of the 4 cell types may potentially be
dependent on individual APOBEC levels in each cell type [42]. It
has been shown earlier that XMRV is resistant to human
APOBEC 3G (hA3G) and that the levels of hA3G are down-
regulated by XMRV in LNCaP and DU145 cells thereby
supporting efficient viral infection in these cell types [42,43]. The
hA3G is down regulated by the human immunodeficiency virus-1
(HIV-1) vif protein during infection. However, since XMRV lacks
vif, an alternate mechanism of hA3G down regulation has been
suggested [43]. PBMCs on the other hand, seemingly possess
significantly higher levels of h3AG and hence are relatively resistant
to XMRV infection [42].
The two microRNAs (miR-193a-3p and miRPlus-E1245) are
moderately regulated in the four cell types. However, it is
interesting to note that within the four cell types, miR-193a-3p is
down regulated over time, while miRPlus-E1245 however
exhibited varied levels of expression profile between the 4 cell
Figure 3. Heat map and unsupervised Hierarchical Clustering.
The clustering is performed on all samples and on all microRNAs with
standard deviation over 1. Each row represents one microRNA and each
column represents one sample. The microRNA clustering tree is shown
on the left. The color scale shown at the bottom illustrates the relative
expression level of a microRNA across all samples: red color represents
an expression level above mean, green color represents expression level
lower than the mean.
doi:10.1371/journal.pone.0032853.g003
Figure 4. Identification of top 25 commonly regulated micro-
RNAs in the four cell types tested. As seen in this venn diagram
two miRs are commonly regulated in all four cell types. While 6 miRs
were commonly regulated in 3 of the 4 cell types tested, 11 miRs were
found to be common in at least 2 of the 4 cell types. Cell-type specific
miR regulation was found to be 11 miRs each for PBL and DU145 cell
lines and 16 miRs each were regulated in LNCaP and MDM cells.
doi:10.1371/journal.pone.0032853.g004
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regulation in LNCaP and DU156 cell types. Since the miRPlus-
E1245 has not been annotated and not submitted in the miRNA
database yet by its discoverer, the Exiqon Inc., Denmark, it is not
feasible at this time to identify its potential targets. Therefore, we
only analyzed the miR-193a-3p for its tentative mRNA targets by 3
different online programs as indicated in Table 1. Target
Prediction by miRDB, TargetScan and microRNA.org programs
revealed that out of the top 10 mRNA targets that were identified
individually by these 3 different softwares, 1 target mRNA was
picked by all three programs and 5 mRNA targets were commonly
flagged at least by two different programs. Of the six predicted
mRNA targets for miR-193a-3p, five mRNA targets were related
to tumorogenesis or suppression. Interestingly 3 mRNA targets,
namely SON DNA bindingdomain (SON), Friend Leukemia Virus
Integration 1 (FLI1) and v-erb-erythroblastic leukemia viral
oncogene homolog 4 (ERBB4) have been implicated with virus/
virus infections. Of the 3, the FLI1 protein (or its homolog) may
have a potential role in XMRV infection as this protein has already
been implicated inFriend Leukemia Virus which also is a retrovirus
causing tumorigenesis [44,45]. The FLI1 is a protein responsible
for the integration of the viral gene into the host DNA thereby
leading to carcinogenesis [44,45]. The human genome was recently
analyzed for potential XMRV genome integration sites and results
revealed that the virus had integration sites in at least 11 of the 23
chromosomes [46]. Hence it is to be seen whether this particular
host mRNA target is being modulated by miR-193a-3p during
XMRV infection. Ofthe other two,while the SON protein bindsto
hepatitis B virus (HBV) DNA and exhibits sequence similarity to
other oncoproteins, the ERBB4 protein affects mitogenesis and cell
differentiation and furthermore it is known that mutations within
this gene are associated with cancer [47–49].
More pertinently, while the qPCR results revealed robust
infection in two cell types (LNCaP and DU145 cells) and moderate
infection in the other two tested cell types (PBLs and MDMs), what
is common to all 4 cell types is the regulation of the two miRNAs
(miR-193a-3p and miRPlus-E1245) during XMRV infection
regardless of the level of infectivity, virus titer or dose of the
infection. This is the first report indicating the expression and
regulation of miRs during XMRV infection of human cells. It
remains to be seen whether the same set of miRNAs are up
regulated during infection of murine cells or cell lines.
The current findings reported here certainly demonstrate that
XMRV infection modulates miRNAs in the host cells as is the case
with many other viruses that are pathogenic to humans [20–23]. In
human retroviruses such as HIV-1 and HTLV-1, the role of
microRNAs has already been demonstrated [50–54]. Many of
these exquisite studies have clearly shown how certain miRs up
regulate or down regulate certain host genes/proteins to promote
viral infection or disease pathogenesis [50–52,54,55]. In fact, it is
now known that HIV-1 and other viruses themselves code for
microRNAs, which play a critical regulatory role during virus
infection [50,56]. Our studies also demonstrate that miRNA
profiles are different in XMRV-infected prostate cancer cell lines
Figure 5. Tabular representation of top 25 most differentially expressed miRs in the 4 cell types (D-DU145; L-LNCaP; P-PBL, and M-
MDMs). Yellow represents miRNAs present in all 4 lists (hsa-miR-193a-3p and hsa-miRPlus-E1245), blue represents miRNA present in 3 out of 4 lists
and dark-red represents miRNAs present in 2 out of 4 lists.
doi:10.1371/journal.pone.0032853.g005
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S.No Gene description Gene symbol miRDB TargetScan microRNA.org
1 SON DNA binding domain SON ++ +
2 Friend Leukemia virus Integration 1 FLI1 ++
3 Abl Interactor 2 ABI2 ++
4 v-erb-erythroblastic leukemia viral
oncogene homolog 4 (avian)
ERBB4 ++
5 Solute carrier family 10 (Na/bile acid
cotransporter family), member 6
SLC10A6 ++
6 FH2 domain containing 1 FHDC1 ++
Top 10 genes commonly picked by at least two different prediction programs are indicated.
doi:10.1371/journal.pone.0032853.t001
Figure 6. Differential expression of miR-193a-3p and miRPlus-E1245. By subtracting the miR expression values from the virus-infected and
mock-infected (M-V) and further subtracting the values between the time points (nT6nT24 and nT6-nT48) an expression profile was generated for
the two miRs as mentioned above. It can be observed that miR-193a-3p is down regulated over time due to virus infection in all 4 cell types, whereas
miRPlus-E1245 exhibits varied levels of expression profile between the 4 cell types.
doi:10.1371/journal.pone.0032853.g006
Cellular microRNA Profiles of XMRV Infection
PLoS ONE | www.plosone.org 7 March 2012 | Volume 7 | Issue 3 | e32853compared to primary hematopoietic cells, suggesting that miRNAs
could play a role in XMRV infection, and serve as markers of
XMRV infection in cultured cells.
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